BioWorld Asia

Dec. 22, 2010

EpiTherapeutics, Abbott in Epigenetics Oncology Deal

EpiTherapeutics ApS, which is developing cancer drugs based on epigenetics targets, entered its first drug discovery pact, with Abbott, of Abbott Park, Ill. (BioWorld International) Read More

Xention Spins Out Provesica to Advance Bladder Drug

Genomics of Lung Cancer Yields a New Drug Target

NovImmune Tops Off Cash with $20M for Antibody Trials

Two Biotechs Merge to Form PsiOxus Therapeutics

Proximagen Picks up GSK's Discarded CNS Programs

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 24, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for July 21, 2026

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Science

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

To viral or not to viral: In vivo CAR T debates delivery tech

BioWorld Asia

The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...

Other news to note for July 22, 2026

BioWorld

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...